Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCZ696 vs olmesartan in essential hypertensive patients not responsive to olmesartan
2013-001783-36Phase 3Terminated
- Sponsor
- Novartis
- Start
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sacubitril + valsartan in essential hypertension (2 arms), sponsored by Novartis. Primary endpoint: Change from baseline in 24-hour mean ambulatory systolic blood pressure. Started Jul 2013; status: terminated.
02
Drugs
sacubitril + valsartan
03
Conditions
essential hypertension
Beyond the preview
Go deeper on 2013-001783-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001783-36.